ADAM17 and hepatocellular carcinoma: MiR-122 represses HCC by targeting multiple genes involved in carcinogenesis [117], such as cyclin G1 [118] and ADAM Metallopeptidase Domain 17 (ADAM17) [119], involved in proliferation and EMT, respectively.